AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21557525 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab 500 mg plus MTX
Number of subjects: 748
Study 21557525 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab 1,000 mg plus MTX
Number of subjects: 748
Study 21557525 — intervention group
Group type: COMPARATOR
Intervention: MTX alone
Number of subjects: 748
Study 21557525 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab plus MTX (both doses)
Number of subjects: 748
Study 19490279 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone Support System (TSS)
Number of subjects: 0
Study 19490279 — intervention group
Group type: COMPARATOR
Intervention: Internet Support (WEB)
Number of subjects: 0
Study 16741262 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine (7 g)
Number of subjects: 8
Study 16741262 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (Ex)
Number of subjects: 8
Study 16741262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 16741262 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine + Exercise (Arg+Ex)
Number of subjects: 8
Study 14734396 — intervention group
Group type: EXPERIMENTAL
Intervention: Triage and transportation to MIU by ambulance crews
Number of subjects: 344
Study 14734396 — intervention group
Group type: COMPARATOR
Intervention: Normal practice (control group)
Number of subjects: 344
Study 10945489 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine + BSC
Number of subjects: 300
Study 10945489 — intervention group
Group type: COMPARATOR
Intervention: BSC alone
Number of subjects: 300
Study 9128274 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell Hemoglobin Distribution Width (CHDW) < 3.05
Number of subjects: 0
Study 9128274 — intervention group
Group type: EXPERIMENTAL
Intervention: CHDW/RBC ratio of 0.57
Number of subjects: 0
Study 8404805 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency-planning exercise
Number of subjects: 291
Study 8404805 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhancing attitude-behavior correspondence (handling condoms)
Number of subjects: 291
Study 8404805 — intervention group
Group type: COMPARATOR
Intervention: Standard education
Number of subjects: 291
Study 3544622 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (40 mg/day)
Number of subjects: 24
Study 3544622 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (200 mg/day)
Number of subjects: 24
Study 28332301 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 87
Study 28332301 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 87
Study 28332301 — intervention group
Group type: COMPARATOR
Intervention: Gliclazide
Number of subjects: 87
Study 25174679 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthelminthic drug administration
Number of subjects: 115
Study 25174679 — intervention group
Group type: EXPERIMENTAL
Intervention: FLOTAC technique
Number of subjects: 115
Study 25174679 — intervention group
Group type: COMPARATOR
Intervention: Kato-Katz technique
Number of subjects: 115
Study 22836602 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol ingestion (vodka and orange juice; ALC)
Number of subjects: 9
Study 22836602 — intervention group
Group type: COMPARATOR
Intervention: Control (caloric and taste‐matched nonalcoholic beverage; CONT)
Number of subjects: 9
Study 21493741 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 0
Study 21493741 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 18637983 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeding assistance intervention (twice per day, 5 days per week for 24 weeks)
Number of subjects: 76
Study 18637983 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 76
Study 17133204 — intervention group
Group type: EXPERIMENTAL
Intervention: DAART-Plus (colocated medical, case management, and referral to substance abuse services)
Number of subjects: 72
Study 17133204 — intervention group
Group type: COMPARATOR
Intervention: DAART (self-administered therapy)
Number of subjects: 72
Study 12649925 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE‐I(+) group (n = 74)
Number of subjects: 246
Study 12649925 — intervention group
Group type: COMPARATOR
Intervention: ACE‐I(‐) group (n = 172)
Number of subjects: 246
Study 12649925 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE‐I(+) group
Number of subjects: 246
Study 12649925 — intervention group
Group type: COMPARATOR
Intervention: ACE‐I(‐) group
Number of subjects: 246
Study 12649925 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE‐I(+) group (among 104 patients with Paf for < 3 months)
Number of subjects: 246
Study 12649925 — intervention group
Group type: COMPARATOR
Intervention: ACE‐I(‐) group (among 104 patients with Paf for < 3 months)
Number of subjects: 246
Study 10890645 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume Assist (VA) at 8 cm H2O/L and 12 cm H2O/L
Number of subjects: 15
Study 10890645 — intervention group
Group type: COMPARATOR
Intervention: Pressure Support Ventilation (PSV) at 10 cm H2O and 15 cm H2O
Number of subjects: 15
Study 8684741 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated oxytocin infusion plus 10-mg PGE2 vaginal suppository every 6 hours
Number of subjects: 154
Study 8684741 — intervention group
Group type: COMPARATOR
Intervention: 20-mg PGE2 vaginal suppository every 4 hours
Number of subjects: 154
Study 2032371 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy sessions with a clinical psychologist, including discussions and relaxation techniques.
Number of subjects: 2
Study 2032371 — intervention group
Group type: COMPARATOR
Intervention: Matched control group (not specified what intervention they received).
Number of subjects: 2
Study 6404472 — intervention group
Group type: EXPERIMENTAL
Intervention: Photocoagulation
Number of subjects: 268
Study 6404472 — intervention group
Group type: COMPARATOR
Intervention: Rubber band ligation
Number of subjects: 268
Study 30472302 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Number of subjects: 57
Study 30472302 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine hydrochloride with lidocaine
Number of subjects: 57
Study 30472302 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine and Bupivacaine hydrochloride with lidocaine
Number of subjects: 57
Study 30072176 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Rehabilitation Training (CRT)
Number of subjects: 168
Study 27751212 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-severe PIVH (grades III and IV)
Number of subjects: 56
Study 27751212 — intervention group
Group type: COMPARATOR
Intervention: Mild PIVH (grades I and II)
Number of subjects: 56
Study 27751212 — intervention group
Group type: COMPARATOR
Intervention: Control group (gestational age-matched normal preterm without ICH)
Number of subjects: 56
Study 24660645 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 20
Study 24660645 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (laser simulation)
Number of subjects: 20
Study 22345050 — intervention group
Group type: EXPERIMENTAL
Intervention: Test mirtazapine 30 mg single-dose formulation
Number of subjects: 31
Study 22345050 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation
Number of subjects: 31
Study 20412743 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol metabolism modulation
Number of subjects: 0
Study 20412743 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential cholesterol modulators (e.g., ATP‐binding cassette transporter A1, LDL receptor)
Number of subjects: 0
Study 20412743 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracellular cholesterol accumulation
Number of subjects: 0
Study 20412743 — intervention group
Group type: EXPERIMENTAL
Intervention: Different lipoprotein classes
Number of subjects: 0
Study 18052562 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (300 mg twice daily) for 4 weeks
Number of subjects: 60
Study 18052562 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 60
Study 16135679 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dose inhaled corticosteroids (fluticasone propionate 200 mug/day) plus salmeterol
Number of subjects: 4576
Study 16135679 — intervention group
Group type: COMPARATOR
Intervention: Higher doses of inhaled corticosteroids (ICS)
Number of subjects: 4576
Study 16135679 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 4576
Study 12431824 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with gemcitabine/cisplatin
Number of subjects: 0
Study 12431824 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery plus induction gemcitabine/cisplatin
Number of subjects: 0
Study 12431824 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study 10598596 — intervention group
Group type: COMPARATOR
Intervention: 1.5 l lactated Ringer's solution (LR)
Number of subjects: 36
Study 10598596 — intervention group
Group type: COMPARATOR
Intervention: 0.5 l hydroxyethylstarch solution, 6% (0.5 l HES)
Number of subjects: 36
Study 10598596 — intervention group
Group type: COMPARATOR
Intervention: 1.0 l hydroxyethylstarch solution, 6% (1.0 l HES)
Number of subjects: 36
Study 8949271 — intervention group
Group type: EXPERIMENTAL
Intervention: Totally pre peritoneal (TPP) laparoscopic surgery
Number of subjects: 100
Study 8949271 — intervention group
Group type: COMPARATOR
Intervention: Stoppa procedure (open)
Number of subjects: 100
Study 1747702 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine 400 mg daily
Number of subjects: 104
Study 1747702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 7044351 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% timolol maleate
Number of subjects: 32
Study 7044351 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% epinephrine hydrochloride
Number of subjects: 32
Study 7044351 — intervention group
Group type: COMPARATOR
Intervention: 0.5% timolol maleate and 2% epinephrine hydrochloride
Number of subjects: 32
Study 7044351 — intervention group
Group type: COMPARATOR
Intervention: 2% epinephrine hydrochloride and 0.5% timolol maleate
Number of subjects: 32
Study 30885778 — intervention group
Group type: EXPERIMENTAL
Intervention: Clip closure
Number of subjects: 919
Study 30885778 — intervention group
Group type: COMPARATOR
Intervention: Control (no closure)
Number of subjects: 919
Study 30885778 — intervention group
Group type: EXPERIMENTAL
Intervention: Clip closure (proximal large polyp)
Number of subjects: 919
Study 30885778 — intervention group
Group type: COMPARATOR
Intervention: Control (proximal large polyp)
Number of subjects: 919
Study 30885778 — intervention group
Group type: EXPERIMENTAL
Intervention: Clip closure (distal large polyp)
Number of subjects: 919
Study 30885778 — intervention group
Group type: COMPARATOR
Intervention: Control (distal large polyp)
Number of subjects: 919
Study 28159357 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (N = 31)
Number of subjects: 61
Study 28159357 — intervention group
Group type: COMPARATOR
Intervention: Validation group (N = 30)
Number of subjects: 61
Study 25398660 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid 0.15 % and vitamin B12 eye drops (n=32)
Number of subjects: 101
Study 25398660 — intervention group
Group type: COMPARATOR
Intervention: No treatment (n=29)
Number of subjects: 101
Study 25398660 — intervention group
Group type: COMPARATOR
Intervention: Patients without dry eye (n=42)
Number of subjects: 101
Study 24226495 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral spinal anesthesia with 50 mg hyperbaric prilocaine 2%
Number of subjects: 80
Study 24226495 — intervention group
Group type: COMPARATOR
Intervention: Bilateral spinal anesthesia with 50 mg hyperbaric prilocaine 2%
Number of subjects: 80
Study 20967920 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control group
Number of subjects: 134
Study 20014597 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ropivacaine (0.2%)
Number of subjects: 66
Study 20014597 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ropivacaine (0.375%)
Number of subjects: 66
Study 20014597 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 66
Study 17303970 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0703 12.5 mg
Number of subjects: 121
Study 17303970 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0703 50 mg
Number of subjects: 121
Study 17303970 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0703 100 mg
Number of subjects: 121
Study 17303970 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 121
Study 17303970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 15566375 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemplars used in inferential prediction task after classification
Number of subjects: 0
Study 15566375 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemplars with multiple uses in feature listing
Number of subjects: 0
Study 11097697 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (75 mg/kg, maximum 2.5 g)
Number of subjects: 54
Study 11097697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 11097697 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 54
Study 11097697 — intervention group
Group type: COMPARATOR
Intervention: Magnesium sulfate and Placebo
Number of subjects: 54
Study 9185026 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors (patients who believed they could tell when their BP was up)
Number of subjects: 102
Study 9185026 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors
Number of subjects: 102
Study 9185026 — intervention group
Group type: COMPARATOR
Intervention: Non-predictors
Number of subjects: 102
Study 1587971 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 100 micrograms/kg
Number of subjects: 24
Study 1587971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 3835497 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam (800‐6,400 mg)
Number of subjects: 2
Study 3835497 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam-lecithin (4,800 mg and 25 g, respectively)
Number of subjects: 2
Study 3835497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 2895689 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg.kg‐1
Number of subjects: 40
Study 2895689 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium 0.1 mg.kg‐1
Number of subjects: 40
Study 2895689 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium and Vecuronium
Number of subjects: 40
Study 31626219 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole at a dose of up to 20 mg/day
Number of subjects: 90
Study 31626219 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine at a dose of up to 600 mg/day
Number of subjects: 90
Study 31626219 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol at a dose of up to 30 mg/day
Number of subjects: 90
Study 28971849 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumer-behavior intervention (enhanced online ordering system)
Number of subjects: 2714
Study 28971849 — intervention group
Group type: COMPARATOR
Intervention: Control (standard online ordering only)
Number of subjects: 2714
Study 25536101 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical Time Intervention (CTI) for 9 months
Number of subjects: 150
Study 25536101 — intervention group
Group type: COMPARATOR
Intervention: Usual services only
Number of subjects: 150
Study 23238778 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosapride (5 mg, 3/day)
Number of subjects: 119
Study 23238778 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (15 mg, 1/day)
Number of subjects: 119
Study 23238778 — intervention group
Group type: COMPARATOR
Intervention: Control (without medication)
Number of subjects: 119
Study 21560152 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical injections of 100 U of onabotulinumtoxinA into bladder body
Number of subjects: 105
Study 21560152 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical injections of 100 U of onabotulinumtoxinA into bladder body/trigone
Number of subjects: 105
Study 21560152 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical injections of 100 U of onabotulinumtoxinA into bladder base/trigone
Number of subjects: 105
Study 21560152 — intervention group
Group type: COMPARATOR
Intervention: All groups (bladder body, bladder body/trigone, bladder base/trigone)
Number of subjects: 105
Study 18469650 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium alloy pins (Ti6Al4V)
Number of subjects: 80
Study 18469650 — intervention group
Group type: COMPARATOR
Intervention: Stainless steel pins (Ss)
Number of subjects: 80
Study 18469650 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Ti6Al4V and Ss)
Number of subjects: 80
Study 16507847 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum strategy (SS)
Number of subjects: 117
Study 16507847 — intervention group
Group type: COMPARATOR
Intervention: Clinical strategy (CS)
Number of subjects: 117
Study 16507847 — intervention group
Group type: EXPERIMENTAL
Intervention: Both strategies
Number of subjects: 117
Study 12943937 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Sleep Deprivation (TSD)
Number of subjects: 39
Study 12943937 — intervention group
Group type: COMPARATOR
Intervention: Late Partial Sleep Deprivation (LPSD)
Number of subjects: 39
Study 11087303 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercises to increase the force of the diagonal trunk muscle systems
Number of subjects: 44
Study 11087303 — intervention group
Group type: COMPARATOR
Intervention: Training of the longitudinal trunk muscle systems
Number of subjects: 44
Study 11087303 — intervention group
Group type: COMPARATOR
Intervention: Instructions to refrain from exercises
Number of subjects: 44
Study 8659732 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA)
Number of subjects: 30
Study 1357450 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularisation (angioplasty or coronary bypass surgery)
Number of subjects: 26
Study 1357450 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment (calcium-channel-blocking drug plus aspirin)
Number of subjects: 26
Study 4013624 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (0.014 mg/kg)
Number of subjects: 100
Study 4013624 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 100
Study 29985942 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-derived CD4+ T cells
Number of subjects: 0
Study 27926448 — intervention group
Group type: EXPERIMENTAL
Intervention: Competition condition
Number of subjects: 93
Study 27926448 — intervention group
Group type: EXPERIMENTAL
Intervention: Rematch competitions
Number of subjects: 93
Study 27926448 — intervention group
Group type: COMPARATOR
Intervention: Noncompetition control conditions
Number of subjects: 93
Study 24671721 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercapnic ventilation (tcPCO2 50-60 mmHg)
Number of subjects: 22
Study 24671721 — intervention group
Group type: EXPERIMENTAL
Intervention: Normocapnic ventilation (tcPCO2 35-45 mmHg)
Number of subjects: 22
Study 24671721 — intervention group
Group type: COMPARATOR
Intervention: Normocapnic ELBW infants
Number of subjects: 22
Study 24671721 — intervention group
Group type: COMPARATOR
Intervention: Hypercapnic ELBW infants
Number of subjects: 22
Study 23213992 — intervention group
Group type: EXPERIMENTAL
Intervention: Chuzhen therapy
Number of subjects: 153
Study 23213992 — intervention group
Group type: COMPARATOR
Intervention: Massage therapy
Number of subjects: 153
Study 20931060 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation plus oral rehydration salts (ORS)
Number of subjects: 0
Study 20931060 — intervention group
Group type: COMPARATOR
Intervention: Oral rehydration salts (ORS)
Number of subjects: 0
Study 18816596 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 6 mg administered intravenously intraoperatively (Arm A)
Number of subjects: 196
Study 18816596 — intervention group
Group type: COMPARATOR
Intervention: No steroids (Arm B)
Number of subjects: 196
Study 15819344 — intervention group
Group type: EXPERIMENTAL
Intervention: One-bottle, ethanol-based adhesive
Number of subjects: 57
Study 15819344 — intervention group
Group type: EXPERIMENTAL
Intervention: One-bottle, solvent-free adhesive
Number of subjects: 57
Study 15819344 — intervention group
Group type: COMPARATOR
Intervention: Two-bottle, water-based adhesive
Number of subjects: 57
Study 15819344 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall retention rate for all restorations
Number of subjects: 57
Study 15819344 — intervention group
Group type: EXPERIMENTAL
Intervention: Marginal integrity, marginal discoloration, and air sensitivity
Number of subjects: 57
Study 12461302 — intervention group
Group type: EXPERIMENTAL
Intervention: Information about the storage capabilities of a home blood pressure measuring device
Number of subjects: 48
Study 12461302 — intervention group
Group type: COMPARATOR
Intervention: No information about the storage capabilities of a home blood pressure measuring device
Number of subjects: 48
Study 11028549 — intervention group
Group type: EXPERIMENTAL
Intervention: Biobrane
Number of subjects: 89
Study 11028549 — intervention group
Group type: COMPARATOR
Intervention: Topical antimicrobials and dressing changes
Number of subjects: 89
Study 8761540 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calcium dialysate solution (LCa, 1.0 mmol/L)
Number of subjects: 64
Study 8761540 — intervention group
Group type: COMPARATOR
Intervention: Standard-calcium dialysate solution (SCa, 1.75 mmol/L)
Number of subjects: 64
Study 8761540 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate (CaCO3) as oral phosphate binder
Number of subjects: 64
Study 8761540 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminium hydroxide (Al(OH)3)
Number of subjects: 64
Study 8761540 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol (0.25 microgram/day per os)
Number of subjects: 64
Study 8761540 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone mineral density measurements
Number of subjects: 64
Study 8761540 — intervention group
Group type: EXPERIMENTAL
Intervention: Skeletal x-ray films
Number of subjects: 64
Study 1550410 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam 6 mg once daily
Number of subjects: 160